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Editorial
Non-alcoholic fatty liver disease (NAFLD) is the most prevalent
hepatic problem in Western and Asian countries where it can affect
more than 30% of people [1]. NAFLD pathological characteristic is a
fat infiltration of the hepatocytes (hepatic steatosis) in subjects who are
mild or no alcohol drinkers and do not have other secondary causes of
hepatic lipid accumulation. In one fifth of affected patients, NAFLD
can evolve in a liver inflammatory damage, which is associated with
oxidative stress, cytolysis, and fibrosis (steatohepatitis) [2]. Of these
patients, more than one-third progress to liver cirrhosis and a small
part can develop hepatocarcinoma along years. It’s not clear why some
patients with NAFLD evolve to non-alcoholic steatohepatitis (NASH)
while others remain stable over years, though a role of intestinal
inflammation, gut dysbiosis, and hypovitaminosis D has been recently
proposed [3]. Consistently, subjects at high risk to develop NAFLD are
those affected by obesity, type 2 diabetes mellitus, and other conditions
associated with insulin resistance or hyperinsulinemia such as
hypertension, dyslipidemia, polycystic ovary disease, and metabolic
syndrome, as well as patients with chronic inflammatory bowel
diseases [4]. Patients with NAFLD are characterized by increased
circulatory levels of triglycerides and free fatty acids (FFAs) that come
from the adipose tissue through the lipolytic process, from the hepatic
lipid de-novo synthesis, and to a minor extent from food intake. Both
insulin resistance and hyperinsulinemia in predisposed subjects are
associated with a visceral fat distribution and are responsible for the
high level of circulatory FFAs [5]. FFAs enter and accumulate in
insulin-resistant hepatocytes and by esterification with glycerol
increase hepatic triglycerides synthesis and very low-density
lipoproteins (VLDL) production; thus, favoring hypertriglyceridemia.
The overflow of plasma lipids and lipid metabolites in non-adipose
tissues induces “lipotoxicity”, a pathological process characterized by
lipids accumulation in liver and in other organs such as heart, kidney,
pancreas, and skeletal muscle [6]. This process is responsible for the
development and progression of heart and kidney failure, obesity, and
diabetes, as well as for the systemic release of inflammatory cytokines.
System cytokines maintain chronic subclinical inflammation, induce
oxidative stress and endothelial dysfunction, and predispose to the
atherosclerotic process [7]. Although NAFLD has been considered as
the hepatic manifestation of the metabolic syndrome, evidence has
shown that NAFLD is associated with cardiovascular morbidity and
mortality independently of metabolic syndrome. Therefore, other than
pro-cirrhotic, NAFLD had to be considered an important modifiable
risk factor for cardiovascular diseases [8].
As a result of the high clinical impact of NAFLD in the general
population, treatment of NAFLD is essential. However, despite
promising studies have been conducted with several agents, so far no
strong evidence supports a specific pharmacological treatment. Weight
loss is the first efficacious non-pharmacological intervention that
should be applied to all patients with NAFLD and avoid even mild
alcohol consumption in these patients could be a good rule of reason,
as well. Hypocaloric diet and regular physical activity in overweight
and obese patients should induce at least 7 to 10% of weight reduction
to exert their beneficial effect on liver steatosis and steatohepatitis.
Consistently, bariatric surgery has shown to be highly efficacious in
severe obese patients with NAFLD/NASH [9]. Thiazolidinediones
(pioglitazone) and antioxidant (especially vitamin E) are those
pharmacological treatments that are more frequently used. However,
positive effects of the insulin-sensitizer pioglitazone are
counterbalanced by a significant weight gain and results with
antioxidants are discordant mostly because they have been used in
different formulations and dosages or associated with different lifestyle
modifications. Other pharmacological treatments may include the
angiotensin-II receptor blocker telmisartan, L-carnitine, and the
promising omega-3 polyunsaturated fatty acids (PUFA) [10].
Omega-3 PUFA has been studied in patients with NAFLD/NASH
because of their potential hypotriglyceridemic, insulin-sensitizer, and
anti-inflammatory effects [11]. Observational studied have shown that
patients with NAFLD have low plasma levels of omega-3 respect to
omega-6 PUFA and other studies founded an association between
NAFLD and high consumption of saturated fatty acids respect to
omega-3 PUFA. Several preliminary studies on the effect of omega-3
PUFA intake on different aspects of NAFLD/NASH (biomarkers of
hepatic damage, liver fat accumulation, and liver fibrosis) have been
published with some promising results. Hodson et al. [12] showed that
a significant cell enrichment of docosahexaenoic acid after omega-3
PUFA supplementation in patients with NAFLD improved hepatic
insulin sensitivity, reduced fasting and post-prandial plasma
triglycerides levels and fasting hepatic de-novo lipogenesis, and
improved lipid beta-oxidation [12]. Most importantly, omega-3 PUFA
treatment can reduce radiological and histological findings of liver
steatosis and fibrosis in non-cirrhotic patients [13]. Additionally,
omega-3 PUFA intake is inversely related with the risk of
hepatocarcinoma [14] and these fatty acids can be beneficial in
cardiovascular disease prevention, conditions frequently associated
with NAFLD/NASH morbidity and mortality [15]. Very recently, He et
al. [16] published an updated meta-analysis of seven randomized
controlled trials (RCT) on the effectiveness of omega-3 PUFA in
patients with NAFLD/NASH. This study included 442 non-diabetic
patients in which omega-3 PUFA significantly improved lipid profile
(reduced triglycerides and total cholesterol and increased HDL-
cholesterol) and reduced plasma alanine aminotransferase levels, but
with unclear effects on signs of liver steatosis and fibrosis and with a
significant heterogeneity between studies [16]. Similar findings were
showed also in a meta-analysis of 4 RCT that included 263 children
and adolescents with NAFLD. Results of this meta-analysis
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demonstrated that omega-3 PUFA supplementation reduce the hepatic
steatosis grade on ultrasound and liver enzymes plasma levels after at
least 1 year of treatment [17]. However, in these patients the treatment
does not reduce inflammatory markers and do not modify any
metabolic syndrome components.
These results, although encourage the use of omega-3 PUFA for
NAFLD prevention, remain too weak to support their routinely use in
clinical practice. In some trials of patients with NASH, omega-3 PUFA
intake fails to be effective on signs of liver fibrosis. Additionally, some
controversies on the use of omega-3 PUFA in metabolic patients could
limit their usefulness in the treatment of NAFLD/NASH. In the recent
trial of Dasarathy et al. [18] on diabetic patients with NASH, omega-3
PUFA treatment did not show any beneficial effect on histological
findings of liver steatohepatitis but, most importantly, the treatment
impaired glucose tolerance and insulin sensitivity respect to placebo
[18]. Concernedly, similar findings were noted in overweight men in
which omega-3 PUFA from krill oil worsened insulin sensitivity [19],
and in a stratified analysis of cohort studies where consumption of
omega-3 PUFA rich fish/seafood in Caucasian populations were
associated with a 38% higher (95% C.I. 13-70%) relative risk to develop
a type 2 diabetes [20]. A predisposition to develop type 2 diabetes after
omega-3 PUFA intake in Americans but not in Asians was also
supported by a meta-analysis of 16 observational studies involving
about 700,000 participants [21]. Additionally, results of some
experimental studies have raised alarms about the use of omega-3
PUFA in NASH and other hepatic diseases. In a mouse model of
steatohepatitis, the effective incorporation of omega-3 PUFA in
hepatocytes induced a more severe necro-inflammation and fibrosis of
the liver respect to olive oil treatment [22] and a similar pro-fibrotic
effect of omega-3 PUFA were demonstrated in mice treated with
carbon tetrachloride [23] and in a rat model of biliary atresia [24].
Under the light of these results, the use of omega-3 PUFA in the
treatment of NAFLD/NASH is still far from getting an evidence based
indication and further well conducted large RCT with histological
demonstration of a benefit from omega-3 intake should be performed.
Omega-3 PUFA, seem to be effective for reducing liver fat probably for
their hypotriglyceridemic effects and they might be useful in early
stages of NAFLD. However, doubts persist on their diabetogenic and
pro-fibrotic risk in NASH patients. Important questions regarding
which source, type, and dose of omega-3 PUFA, how long to treat
patients, and which population will benefit more from omega-PUFA
intake need to be answered. Fortunately, several ongoing clinical trials
with some of these answers will be published soon or in the next few
years. Moreover, new encouraging experimental drugs such as the
farnesoid X receptor agonist obeticholic acid and the peroxisome
proliferator-activated receptors alpha/delta agent elafibranor could
became available as specific or combination treatments for patients
with NAFLD/NASH, thus increasing the pharmacological
armamentarium to treat this widespread disease [25].
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